Early biopsychological changes during masculinizing gender-affirming hormone therapy in AFAB transgender individuals: a 4-month prospective study - Scorecard - MDSpire

Early biopsychological changes during masculinizing gender-affirming hormone therapy in AFAB transgender individuals: a 4-month prospective study

  • By

  • Ludek Fiala

  • Daniela Kestlerova

  • Jakub Nespor

  • Jiri Lenz

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Initial Biopsychological Transformations in AFAB Transgender Individuals Undergoing Masculinizing Hormone Therapy: A 4-Month Prospective Investigation

At a Glance

CategoryDetail
ConditionGender Dysphoria
Key MechanismsEndocrine changes associated with testosterone administration and psychological adaptations.
Target PopulationTransgender individuals assigned female at birth initiating masculinizing hormone therapy.
Care SettingSpecialized clinical center.

Key Highlights

  • Significant reductions in anxiety and trauma-related symptoms observed after 4 months of therapy.
  • Improvements in quality of life measures over time.
  • Endocrine changes included decreased estradiol and increased testosterone levels.
  • Associations between hormonal changes and psychological outcomes were more pronounced after 4 months.
  • Psychological improvements were influenced by psychosocial and treatment-related factors.

Guideline-Based Recommendations

Diagnosis

  • Participants met clinical diagnostic criteria for gender dysphoria.

Management

  • Initiation of masculinizing hormone therapy as indicated for individuals with gender dysphoria.

Monitoring & Follow-up

  • Regular assessments of hormonal parameters and psychological measures at baseline, 2 months, and 4 months.

Risks

  • Potential psychological distress associated with gender dysphoria and treatment initiation.

Patient & Prescribing Data

30 transgender individuals assigned female at birth, aged 18 years or older.

No previous hormonal treatments or surgeries prior to the study; no significant non-adherence to therapy.

Clinical Best Practices

  • Conduct longitudinal assessments to monitor both endocrine and psychological changes.
  • Utilize validated psychometric instruments for psychological evaluation.
  • Consider psychosocial factors in treatment planning and support.

Related Resources & Content

Original Source(s)

Early biopsychological changes during masculinizing gender-affirming hormone therapy in AFAB transgender individuals: a 4-month prospective study

  • by Ludek Fiala, Daniela Kestlerova, Jakub Nespor, Jiri Lenz

  • June 17, 2026

Related Content

Diabetes Self-Care Declines During Breast Cancer Treatment

Patients experience reduced monitoring, emotional distress, and gaps in coordinated care during adjuvant therapy

Premenstrual Disorders Linked to Broad Psychiatric Risk

Swedish study finds two-way associations between premenstrual disorders and psychiatric conditions, with strongest links involving depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, and personality disorders.

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women